Shots:

• Pandion to receive up to $45M as upfront and payments for research and preclinical activities- ~$750M as development and commercial milestone and royalties on global sales of the therapies developed via collaboration
• Pandion to be responsible for drug designing and discovery of bispecific therapies utilizing its modular immune effector and tissue tether platform while Astellas will be responsible for pre/clinical and commercialization activities of the selected candidates developed during the collaboration
• The collaboration will leverage Pandion’s modular biologics and functional immunology expertise with Astellas' development and global commercialization capabilities for the treatment of autoimmune diseases

Click here to­ read full press release/ article 

 Ref: Business wire | Image: Astellas